Inhibrx Biosciences, Inc. (INBX): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$129.82M

Year ended 2025-12-31

-$131.90M

Trailing 12 months to 2026-06-30

2023-12-31 Free Cash Flow (USD) 2025-12-31

Period ended	Free Cash Flow	Change YoY	Source filing
2025-12-31	-$129.82M	n/m	2026-03-19, From 2025-01-01
2024-12-31	-$197.01M	n/m	2026-03-19, From 2024-01-01
2023-12-31	-$197.90M	n/a	2025-03-17, From 2023-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Free Cash Flow	Change YoY
Inhibrx Biosciences, Inc. (INBX)	2025-12-31	-$129.82M	n/m
Scinai Immunotherapeutics Ltd. (SCNI)	2025-12-31	-$6.05M	n/m
Pluri Inc. (PLUR)	2026-06-30	-$20.22M	n/m
Prokidney Corp. (PROK)	2025-12-31	-$135.31M	n/m
Humacyte, Inc. (HUMA)	2025-12-31	-$105.93M	n/m
Aligos Therapeutics, Inc. (ALGS)	2024-12-31	-$80.87M	n/m
Cardiff Oncology, Inc. (CRDF)	2025-12-31	-$37.97M	n/m
Surrozen, Inc. (SRZN)	2025-12-31	-$30.37M	n/m
CRISPR Therapeutics AG (CRSP)	2025-12-31	-$345.93M	n/m

Compare INBX, SCNI, PLUR, PROK side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗